AR115866A1 - Formas cristalinas de un inhibidor de lta4h - Google Patents
Formas cristalinas de un inhibidor de lta4hInfo
- Publication number
- AR115866A1 AR115866A1 ARP190102132A ARP190102132A AR115866A1 AR 115866 A1 AR115866 A1 AR 115866A1 AR P190102132 A ARP190102132 A AR P190102132A AR P190102132 A ARP190102132 A AR P190102132A AR 115866 A1 AR115866 A1 AR 115866A1
- Authority
- AR
- Argentina
- Prior art keywords
- ray
- measured
- temperature
- diffraction pattern
- crystalline form
- Prior art date
Links
- 101000619898 Homo sapiens Leukotriene A-4 hydrolase Proteins 0.000 title 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- -1 4 - ((5-chloro-3-fluoropyridin-2-yl) oxy) phenyl Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Una forma cristalina del compuesto ácido (S)-3-amino-4-(5-(4-((5-cloro-3-fluoropiridin-2-il)oxi)fenil)-2H-tetrazol-2-il)butanoico en su forma libre. Reivindicación 2: La forma cristalina de acuerdo con la reivindicación 1, que comprende la Forma B. Reivindicación 3: La forma cristalina de acuerdo con la reivindicación 1 ó 2, caracterizada por una de las siguientes características: i) un patrón de difracción de rayos X de polvos que comprende picos representativos en términos de 2q en 22,6 ± 0,2 º2q, 24,1 ± 0,2 º2q y 26,3 ± 0,2 º2q, medidos a una temperatura de aproximadamente 25ºC y una longitud de onda de rayos X, l, de 1,5418 Å; (ii) un patrón de difracción de rayos X de polvos que comprende cuatro o más valores 2q seleccionados del grupo que consiste en 11,3 ± 0,2 º2q, 12,8 ± 0,2 º2q, 15,2 ± 0,2 º2q, 19,7 ± 0,2 º2q, 20,0 ± 0,2 º2q, 20,3 ± 0,2 º2q, 21,0 ± 0,2 º2q, 22,6 ± 0,2 º2q, 24,1 ± 0,2 º2q, 24,4 ± 0,2 º2q, 25,1 ± 0,2 º2q, 26,3 ± 0,2 º2q, 28,5 ± 0,2 º2q y 30,0 ± 0,2 º2q, medidos a una temperatura de aproximadamente 25ºC y una longitud de onda de rayos X, l, de 1,5418 Å; y (iii) un patrón de difracción de rayos X de polvos que comprende cinco o más valores 2q seleccionados del grupo que consiste en 11,3 ± 0,2 º2q, 12,8 ± 0,2 º2q, 15,2 ± 0,2 º2q, 19,7 ± 0,2 º2q, 20,0 ± 0,2 º2q, 20,3 ± 0,2 º2q, 21,0 ± 0,2 º2q, 22,6 ± 0,2 º2q, 24,1 ± 0,2 º2q, 24,4 ± 0,2 º2q, 25,1 ± 0,2 º2q, 26,3 ± 0,2 º2q, 28,5 ± 0,2 º2q y 30,0 ± 0,2 º2q, medidos a una temperatura de aproximadamente 25ºC y una longitud de onda de rayos X, l, de 1,5418 Å
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018000278 | 2018-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115866A1 true AR115866A1 (es) | 2021-03-03 |
Family
ID=68072853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102132A AR115866A1 (es) | 2018-07-31 | 2019-07-29 | Formas cristalinas de un inhibidor de lta4h |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11993582B2 (es) |
| EP (2) | EP3830081B1 (es) |
| JP (1) | JP7356496B2 (es) |
| KR (1) | KR102858471B1 (es) |
| CN (1) | CN112513026B (es) |
| AR (1) | AR115866A1 (es) |
| AU (2) | AU2019315778C1 (es) |
| BR (1) | BR112021001435A2 (es) |
| CA (1) | CA3105542A1 (es) |
| CL (1) | CL2021000254A1 (es) |
| ES (1) | ES2984584T3 (es) |
| IL (1) | IL279953A (es) |
| MX (2) | MX2021001069A (es) |
| TW (2) | TWI810338B (es) |
| WO (1) | WO2020026108A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820723A (en) | 1987-08-14 | 1989-04-11 | Eli Lilly And Company | Disubstituted tetrazole leukotriene antagonists and methods for their use thereas |
| AU2003247622A1 (en) | 2002-06-27 | 2004-01-19 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| EP1868605A2 (en) * | 2005-03-31 | 2007-12-26 | Janssen Pharmaceutica, N.V. | Phenyl and pyridyl lta4h modulators |
| NZ566788A (en) * | 2005-09-21 | 2012-10-26 | Decode Genetics Ehf | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation |
| US7968746B2 (en) | 2007-11-06 | 2011-06-28 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| WO2015092740A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
-
2019
- 2019-07-29 US US17/264,333 patent/US11993582B2/en active Active
- 2019-07-29 AU AU2019315778A patent/AU2019315778C1/en active Active
- 2019-07-29 BR BR112021001435-7A patent/BR112021001435A2/pt unknown
- 2019-07-29 CN CN201980050149.1A patent/CN112513026B/zh active Active
- 2019-07-29 TW TW108126714A patent/TWI810338B/zh active
- 2019-07-29 EP EP19779099.1A patent/EP3830081B1/en active Active
- 2019-07-29 KR KR1020217005210A patent/KR102858471B1/ko active Active
- 2019-07-29 CA CA3105542A patent/CA3105542A1/en active Pending
- 2019-07-29 JP JP2021504833A patent/JP7356496B2/ja active Active
- 2019-07-29 ES ES19779099T patent/ES2984584T3/es active Active
- 2019-07-29 MX MX2021001069A patent/MX2021001069A/es unknown
- 2019-07-29 WO PCT/IB2019/056436 patent/WO2020026108A1/en not_active Ceased
- 2019-07-29 AR ARP190102132A patent/AR115866A1/es not_active Application Discontinuation
- 2019-07-29 EP EP24169420.7A patent/EP4389125A3/en active Pending
- 2019-07-29 TW TW112126391A patent/TWI834581B/zh active
-
2021
- 2021-01-04 IL IL279953A patent/IL279953A/en unknown
- 2021-01-27 MX MX2024003339A patent/MX2024003339A/es unknown
- 2021-01-29 CL CL2021000254A patent/CL2021000254A1/es unknown
-
2022
- 2022-03-21 AU AU2022201921A patent/AU2022201921B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022201921A1 (en) | 2022-04-14 |
| KR102858471B1 (ko) | 2025-09-12 |
| KR20210038900A (ko) | 2021-04-08 |
| AU2022201921B2 (en) | 2023-08-03 |
| TW202035388A (zh) | 2020-10-01 |
| AU2019315778C1 (en) | 2022-07-07 |
| JP2021533111A (ja) | 2021-12-02 |
| TWI834581B (zh) | 2024-03-01 |
| TW202342446A (zh) | 2023-11-01 |
| US11993582B2 (en) | 2024-05-28 |
| BR112021001435A2 (pt) | 2021-04-27 |
| AU2019315778B2 (en) | 2022-01-13 |
| MX2021001069A (es) | 2021-04-12 |
| CN112513026B (zh) | 2025-02-25 |
| EP4389125A3 (en) | 2024-09-11 |
| TWI810338B (zh) | 2023-08-01 |
| WO2020026108A1 (en) | 2020-02-06 |
| CL2021000254A1 (es) | 2021-08-20 |
| EP3830081A1 (en) | 2021-06-09 |
| EP4389125A2 (en) | 2024-06-26 |
| IL279953A (en) | 2021-03-01 |
| US20210300897A1 (en) | 2021-09-30 |
| EP3830081B1 (en) | 2024-05-22 |
| JP7356496B2 (ja) | 2023-10-04 |
| MX2024003339A (es) | 2024-04-05 |
| CN112513026A (zh) | 2021-03-16 |
| CA3105542A1 (en) | 2020-02-06 |
| AU2019315778A1 (en) | 2021-01-28 |
| ES2984584T3 (es) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| ES2524380T3 (es) | Sales de raltegravir y formas cristalinas de las mismas | |
| UY38517A (es) | FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
| FI4058151T3 (fi) | Terfenyyliyhdisteen uusi suola | |
| PE20230388A1 (es) | Inhibidor de ret cristalino | |
| JOP20210130A1 (ar) | مثبطات apol1 وطرق استخدامها | |
| CY1122244T1 (el) | Παραγωγα 2-υδροξυ-1-{4-[(4-φαινυλφαινυλ)καρβονυλ]πιπεραζιν-1-υλ}αιθαν-1-ονης και σχετικες ενωσεις ως αναστολεις συνθασης λιπαρου οξεος(fαsν) για την θεραπεια καρκινου | |
| WO2015169270A3 (en) | Light source | |
| CL2021003105A1 (es) | Inhibidores de masp-2 y métodos de uso (divisional de la solicitud no. 202003083) | |
| CH288573A (fr) | Dispositif à trés haute fréquence, pouvant notamment fonctionner comme magnétron. | |
| ES437715A1 (es) | Procedimiento para preparar complejos metalicos de eteres azolilicos. | |
| AR115866A1 (es) | Formas cristalinas de un inhibidor de lta4h | |
| ES308359A1 (es) | Procedimiento para la obtencion de sulfamidas. | |
| Kalaiselvi et al. | Linear and nonlinear optical properties of semiorganic single crystal: l-Alanine cadmium chloride (LACC) | |
| EA200601273A1 (ru) | Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| WO2016137969A3 (en) | Liquid levothyroxine formulations | |
| MX2017013629A (es) | Metodos para mejora hidraulica de cultivos. | |
| BR112022001365A2 (pt) | Formas cristalinas de um inibidor de cd73 | |
| MX2021007505A (es) | Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3. | |
| MX2021003430A (es) | Nuevos oxadiazoles. | |
| EA202191859A1 (ru) | Кристаллические формы 1-(1,2-диметилпропил)-n-этил-5-метил-n-пиридазин-4-ил-пиразол-4-карбоксамида | |
| EA202092393A1 (ru) | Кристаллическое соединение оксазола | |
| MX2023004668A (es) | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. | |
| AR074889A1 (es) | Procedimiento de obtencion de la forma cristalina v de la agomelatina | |
| Amuthambigai et al. | Growth, optical, thermal, mechanical and electrical properties of anhydrous sodium formate single crystals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |